For detailed instructions, read the patient information leaflet
Clinical trials and meta-analyses consistently show that DPP-4 inhibitors produce a modest but clinically meaningful reduction in HbA1c , typically in the range of: 0.5% to 1.0% (approximately 5.5 to 11 mmol/mol) when used as monotherapy or add-on therapy Reductions at the higher end of this range are more likely when baseline HbA1c is significantly elevated For example, sitagliptin has demonstrated reductions of around 0.60.8% in randomised controlled trials, while vildagliptin and saxagliptin show broadly comparable efficacy
Sometimes, people try to take lower doses to save money, but this can make the medication less effective
High blood sugar increases risks for both mom and baby
Treatment for heart disease depends on the specific condition
Related Stories GLP-1 weight loss may reduce first-impression penalties in relationships and hiring Semaglutide outperforms other GLP-1 drugs for weight loss in psychiatric populations Eight-hour eating window sustains long-term weight loss At six months, body mass was significantly decreased by 5%, and both FBM and LBM showed significant reductions of 6% and 1%, respectively